Download PDF
Thromb Haemost 1999; 82(06): 1778
DOI: 10.1055/s-0037-1614920
Letters to the Editor
Schattauer GmbH

Successful Epistaxis Control in a Patient with Glanzmann Thrombasthenia by Increased Bolus Injection Dose of Recombinant Factor VIIa

Ampaiwan Chuansumrit
1   From the Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Chonsuphang Sangkapreecha
1   From the Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Phongjan Hathirat
1   From the Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
› Author Affiliations
Further Information

Publication History

Received 06 July 1999

Accepted 10 August 1999

Publication Date:
10 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Kristensen J, Killander A, Hippe E. et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (Suppl. 01) 159-64.
    PubMedGoogle Scholar
  • 2 Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost (letter) 1996; 75: 981-2.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Revesz T, Arets B, Bierings M, Bos CVD, Duval E. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost (letter) 1998; 80: 353.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
    CrossrefPubMedGoogle Scholar
  • 5 Hoffman M, Monroe III DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coag Fibrinol 1998; 9 (Suppl. 01) S61-5.
    PubMedGoogle Scholar